促肝细胞生长素联合拉米夫定治疗乙型重型肝炎42例的疗效观察  

Observing the Therapeutic Effect of lamivudine Combined with PHGF on 42 Cases of Severe Hepatitis B

作　　者：李玉龙[1] 龚丽霞[1] 王云[1] 

机构地区：[1]攀枝花市第四人民医院,四川攀枝花617061

出　　处：《四川省卫生管理干部学院学报》2009年第2期118-119,共2页Journal of Sichuan Continuing Education College of Medical Sciences

摘　　要：目的:观察促肝细胞生长素联合拉米夫定治疗乙型重型肝炎的临床疗效。方法:选择乙型重型肝炎病人83例,随机分成两组。对照组采用综合治疗,治疗组在对照组的基础上加用促肝细胞生长素120mg/日静滴,拉米夫定口服100mg/日,两组疗程均为1月,观察治疗前后临床、生物化学、病毒学指标变化。结果:(1)治疗组TBIL、ALT、AST明显下降,TBIL下降较对照组更显著(P<0.05)。(2)凝血酶原活动度、白蛋白增加较对照组显著(P<0.05)。(3)HBV-DNA阴转率和负荷载量下降较对照组明显(P<0.001)。(4)治疗组病死率明显低于对照组,11.90%对36.58%(P<0.001)。结论:促肝细胞生长素联合拉米夫定治疗重型肝炎可使临床症状、体征、肝功能有明显改善,抑制HBV复制,提高生存率。Objective： To observe the effect of lamivudine combined with Hepatocyte Growth-promoting Factor （P-HGF） on severe hepatitis B. Methods： 83 cases of patients with severe hepatitis B were randomly divided into therapy group （ n = 42） and control group （ n = 41 ）. The therapy group was given lamivudine 100mg daily combined with P-HGF 120mg iv drip daily and combined therapy for 1 month, and the control group was only given combined therapy. Clinic, biochemical and virologic indexes were determined before and after therapy. Results： In therapy group, values of TBIL, ALT and AST decreased obviously, especially the TBIL （ P 〈 0.05 ）. Values of VIA and albumin in therapy group increased （P 〈 0.05）. Ratio of HBV-DNA being negative sero-conversion and loading vohtme significantly decreased in the therapy group （ P 〈 0.001 ）. In addition, fatality rote in therapy group was also lower than that in control group. Conclusion： Lamivudine with P-HGF therapy can make patients with severe hepatitis B significantly improve their clinical symptoms, signs and liver function, effectively inhibit HBV replication, and increase survival rote.

关 键 词：乙型重型肝炎 促肝细胞生长素 拉米夫定 

分 类 号：R512.62[医药卫生—内科学]